456 related articles for article (PubMed ID: 33357843)
1. Comprehensive Landscape of Heparin Therapy for COVID-19.
Shi C; Tingting W; Li JP; Sullivan MA; Wang C; Wang H; Deng B; Zhang Y
Carbohydr Polym; 2021 Feb; 254():117232. PubMed ID: 33357843
[TBL] [Abstract][Full Text] [Related]
2. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.
Conzelmann C; Müller JA; Perkhofer L; Sparrer KM; Zelikin AN; Münch J; Kleger A
Clin Med (Lond); 2020 Nov; 20(6):e218-e221. PubMed ID: 32863274
[TBL] [Abstract][Full Text] [Related]
3. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
Haggag YA; El-Ashmawy NE; Okasha KM
Med Hypotheses; 2020 Nov; 144():109957. PubMed ID: 32531538
[TBL] [Abstract][Full Text] [Related]
4. Heparin as a therapy for COVID-19: current evidence and future possibilities.
Hippensteel JA; LaRiviere WB; Colbert JF; Langouët-Astrié CJ; Schmidt EP
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L211-L217. PubMed ID: 32519894
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
Benani A; Ben Mkaddem S
Front Immunol; 2020; 11():1841. PubMed ID: 32793246
[TBL] [Abstract][Full Text] [Related]
8. Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?
Giovinazzo G; Gerardi C; Uberti-Foppa C; Lopalco L
Molecules; 2020 Dec; 25(24):. PubMed ID: 33322757
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Bikdeli B; Madhavan MV; Gupta A; Jimenez D; Burton JR; Der Nigoghossian C; Chuich T; Nouri SN; Dreyfus I; Driggin E; Sethi S; Sehgal K; Chatterjee S; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Bertoletti L; Giri J; Cushman M; Quéré I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Tafur AJ; Francese DP; Batra J; Falanga A; Clerkin KJ; Uriel N; Kirtane A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Leon MB; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH;
Thromb Haemost; 2020 Jul; 120(7):1004-1024. PubMed ID: 32473596
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review on sarilumab in COVID-19.
Khiali S; Rezagholizadeh A; Entezari-Maleki T
Expert Opin Biol Ther; 2021 May; 21(5):615-626. PubMed ID: 33161757
[No Abstract] [Full Text] [Related]
11. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
Xiang J; Lu M; Shi M; Cheng X; Kwakwa KA; Davis JL; Su X; Bakewell SJ; Zhang Y; Fontana F; Xu Y; Veis DJ; DiPersio JF; Ratner L; Sanderson RD; Noseda A; Mollah S; Li J; Weilbaecher KN
J Virol; 2022 Apr; 96(7):e0005722. PubMed ID: 35319225
[TBL] [Abstract][Full Text] [Related]
12. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?
Rossi GA; Sacco O; Capizzi A; Mastromarino P
Front Immunol; 2021; 12():670955. PubMed ID: 34093569
[TBL] [Abstract][Full Text] [Related]
13. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from
Song Y; He P; Rodrigues AL; Datta P; Tandon R; Bates JT; Bierdeman MA; Chen C; Dordick J; Zhang F; Linhardt RJ
Mar Drugs; 2021 Nov; 19(12):. PubMed ID: 34940684
[TBL] [Abstract][Full Text] [Related]
16. Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19.
Chérifi F; Laraba-Djebari F
Protein J; 2021 Dec; 40(6):799-841. PubMed ID: 34499333
[TBL] [Abstract][Full Text] [Related]
17. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
18. COVID-19: Some clinical questions after the first 4 months.
Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
[No Abstract] [Full Text] [Related]
19. Niclosamide for Covid-19: bridging the gap.
Al-Kuraishy HM; Al-Gareeb AI; Alzahrani KJ; Alexiou A; Batiha GE
Mol Biol Rep; 2021 Dec; 48(12):8195-8202. PubMed ID: 34664162
[TBL] [Abstract][Full Text] [Related]
20. Non-anticoagulant heparin derivatives for COVID-19 treatment.
Cao M; Qiao M; Sohail M; Zhang X
Int J Biol Macromol; 2023 Jan; 226():974-981. PubMed ID: 36528145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
